1. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Health Sciences Global Business Unit Strategy Steve Rosenberg Senior Vice President and General Manager Oracle Health Sciences Global Business Unit

2. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Safe Harbor Statement The following is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle’s products remains at the sole discretion of Oracle. 2

3. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Clinical R&D - What hasn’t Changed… Improved Outcomes & Care Greater Safety Reduced Costs Streamlined R&D

4. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Clinical R&D - What Continues to Change … Science & Technology Clinical R&D Process Patient Engagement Clinical R&D Landscape

5. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Health Sciences 5 Life Sciences Healthcare Continuum  Accelerate clinical development  Support entire drug safety lifecycle  Enable clinical data aggregation  Power enterprise healthcare analytics  Enable provider/payer integration  Drive personalized medicine  The movement from clinical research to clinical care  Develop collaboration networks for providers and life sciences companies

6. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Life Sciences 6

7. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Optimizing Clinical Research & Development HEALTH SCIENCES CLOUD Safety Lifecycle Analytics and Insights Signal Detection Randomization & Trial Supply Management Clinical Data Aggregation & Reporting Comprehensive Electronic Data Capture Trial Management & Monitoring Trial Management & Monitoring Planning & Budgeting 7

8. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Life Sciences Broadest, best-of-breed applications Focus on integration The highest standards of scalability, security, and privacy 8

9. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Recent Oracle Life Sciences Innovations MOBILITY INFORM, CRA & ANALYTICS KEY PRODUCT & THIRD PARTY INTEGRATIONS DATA MANAGEMENT WORKBENCH INFORM ADVANCED MOLECULAR ANALYTICS MEDICATION ADHERENCE (PROTEUS) CLINICAL MONITORING CLOUD REAL-WORLD SAFETY SURVEILLANCE & COMPARATIVE EFFECTIVENESS RISK BASED MONITORING 9

10. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | FDA-approved ingestible sensors Captures the body’s physiologic responses and behaviors Sends digital health information to a mobile app Oracle’s clinical trial applications customers have exclusive access to real-time data on therapeutic use Medication Adherence 8

11. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |  Medication compliance insight  Better dose selection  Fewer Phase III failures  Improved drug safety Medication Adherence 9

12. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | DEEP-ROOTED COMMITMENT TO DRIVING CLINICAL R&D PROCESS OPTIMIZATION AND ANALYTIC INSIGHTS

13. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Healthcare 13

14. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Healthcare Providers are Facing:  Patient engagement and compliance  Care coordination  Population health  Precision medicine Immediate Focus:  Operational effectiveness  Risk-based revenue Evolves Over Time: Changing business models and risk shiftingMargin pressure – cost, revenue, and volumeConsolidation pressureIncreased complexity in regulation Aging population and management of chronic diseases 14

15. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |  Clinical  Finance  Human Resources  Supply Chain  Claims  Genomics  Research  Clinical Trials  3 rd Party Data Client Developed Apps Oracle Enterprise Healthcare Analytics Third Party Apps Oracle Apps Analyze Normalize Aggregate Enabling Value Through Multiple & Disparate Data Sources Comprehensive Healthcare Data Model Combines Clinical and OMICS Data Data Governance Productized Data Loaders Leverages Oracle Technology Application Choice Powering Enterprise Healthcare Analytics 15

16. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Continuum 16

17. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Delivers:  Biomarker discovery  Protocol validation and patient recruitment  Patient stratification  Safety and comparative effectiveness  Population health  Precision medicine Harnessing Big Data for Life Sciences & Healthcare Volume and availability of data continues to increase Data will have various strengths and significance Velocity of data is coming in faster than ever before Who better than Oracle to attack this? Sensors Petabytes of information Velocity of real-time data Genomics Variety of data sources Real-World Data

18. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Delivers:  Biomarker discovery  Protocol validation and patient recruitment  Patient stratification  Safety and comparative effectiveness  Population health  Precision medicine Sensors Petabytes of information Velocity of real-time data Genomics Variety of data sources Real-World Data Oracle Health Sciences Harnessing Big Data for Life Sciences & Healthcare

19. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Effectiveness of Most Drugs 19 Major DrugDrug Effectiveness Cost of Ineffectiveness to Healthcare System Source: The Personalized Medicine Coalition Hypertension Drugs ACE Inhibitors 10-30%$390 million – $1.2 billion Anti Depressant Drugs SSRIs 20-50%$2.3 billion – $5.8 billion Cholesterol Drugs Statins 30-70%$3.8 billion – $8.8 billion Asthma Drugs Beta-2-agonists 40-70%$560 million – $1.0 billion Heart Failure Drugs Beta Blockers 15-25%$345 million – $575 million

20. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. |  Targeted treatments  More effective trials  Faster time to market  Improved safety  Dramatically lower costs CURRENTTRANSFORMATION Combining Clinical and OMICS data Improving Population Health and Patient Outcomes

21. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Healthcare Provider Participants Life Sciences Participants While Ensuring:  Full control of de-identified data  Protection of Institutional IP  Respect for patient consent  Full HIPAA compliance Oracle Health Sciences Network Cloud-Based Collaborative R&D Network Participants Include: 21

22. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Why Oracle Health Sciences? 22 COMMITTED INVESTMENT IN LIFE SCIENCES & HEALTHCARE INDUSTRIAL STRENGTH CAPABILITY DEEP & BROAD DATA MANAGEMENT BEST-OF-BREED TECHNOLOGY UNMATCHED DOMAIN EXPERTISE INNOVATION & TRANSFORMATION

23. Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | FROM PIPELINE TO PATIENT OPTIMIZING AND TRANSFORMING LIFE SCIENCES AND HEALTHCARE